Ibrutinib May Be Safe, Effective for Chronic Lymphocytic Leukemia with TP53 Aberrations
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, ibrutinib alone may be safe and effective for the first- or second-line treatment of patients with high-risk chronic lymphocytic leukemia (CLL) with TP53 aberrations.
For this single-arm, phase 2 study, researchers at the National Institutes of Health Clinical Center in Bethesda, Maryland, enrolled 47 patients with active CLL with deletion 17p13.1 and four patients with a TP53 aberration without a 17p13.1 deletion. Of those, 35 had previously untreated disease while 16 had relapsed or refractory CLL.
All patients received ibrutinib 420mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. Results showed that among the 33 evaluable previously untreated patients at 24 weeks, 97% (95% CI: 86-100) achieved an objective response. One patient had progressive disease.
Among the 15 evaluable patients with relapsed or refractory disease, 80% (95% CI: 52-96) achieved an objective response. In regard to safety, 24% of patients experienced severe neutropenia, 14% had severe anemia, and 10% experienced severe thrombocytopenia. Six percent of patients experienced grade 3 pneumonia and 2% had grade 3 rash.
The findings suggest that ibrutinib alone should be considered as an option for patients with high-risk CLL with TP53 aberrations for first- or second-line treatment.
Ibrutinib alone may be safe and effective for the first- or second-line treatment of CLL with TP53 aberrations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma